natgillin/translations-raw huggingface dataset:
If you use too many patches or the wrong strength patch If you have stuck on too many patches or the wrong strength patch, take the patches off and contact a doctor straight away. 
Če ste uporabili preveč obližev ali napačno jakost obliža Če ste prilepili prveč obližev ali ste uporabili napačno jakost obliža, jih odstranite in takoj obvestite zdravnika.
• Some medicines used to treat angina (chest pain) or high blood pressure (such as nicardipine). 
• Nekatera zdravila za zdravljenje angine pektoris (bolečina v prsnem košu) ali visokega krvnega tlaka (kot je nikardipin).
Multiplication Factor morphine oral 
Pot uporabe multiplikator morfin peroralna
There is a potential for temperature-dependent increases in fentanyl released from the system resulting in possible overdose and death. 
Obstaja možnost povečanega sproščanja fentanila iz sistema zaradi zvišane temperature, kar lahko vodi v preveliko odmerjanje in smrt.
• Feeling unusually drowsy, breathing that is more slow or shallow than expected. 
• Občutek neobičajne zaspanosti, počasnejše ali bolj plitvo dihanje od običajnega.
Monitoring of the patient for adverse events, which may include hypoventilation, is recommended for at least 48 hours after initiation of DUROGESIC therapy or up-titration of the dose (see section 4.4). 
Spremljanje bolnikov glede neželenih učinkov, ki lahko vključujejo hipoventilacijo, je priporočljivo vsaj 48 ur po začetku zdravljenja z zdravilom DUROGESIC ali po zvečanju odmerka (glejte tudi poglavje 4.4).
Even though impairment of renal function is not expected to affect fentanyl elimination to a clinically relevant extent, caution is advised because fentanyl pharmacokinetics has not been evaluated in this patient population (see section 5.2). 
Čeprav naj okvara ledvic ne bi vplivala na izločanje fentanila v klinično pomembnem obsegu, je priporočljiva previdnost, ker farmakokinetike fentanila v tej populaciji bolnikov niso ocenjevali (glejte poglavje 5.2).
The dose should be titrated individually until a balance between analgesic efficacy and tolerability is attained. 
Odmerek je treba prilagajati individualno, dokler ne dosežemo ravnovesja med analgetično učinkovitostjo in prenašanjem zdravila.
Fentanyl concentrations were measured in more than 250 children aged 2 to 17 years who were applied fentanyl patches in the dose range of 12.5 to 300 mcg/h. 
Koncentracije fentanila so merili pri več kot 250 otrocih, starih od 2 do 17 let, katerim so namestili obliže s fentanilom v jakostih od 12,5 do 300 mikrogramov/h.
This effect could either be due to altered maternal care or a direct effect of fentanyl on the pups. 
Ta učinek bi lahko bil posledica spremenjene nege mladičev s strani samice ali neposrednega učinka fentanila na mladiče.
Fold the patch in the middle and remove each half of the liner separately. 
Obliž po sredini upognemo in odstranimo vsako polovico zaščitne plasti posebej.
If it does not, or if the patch irritates your skin badly, tell your doctor. 
Če ne izgine ali če obliž močno razdraži kožo, se posvetujte z zdravnikom.
• Take the patch out and use straight away 
• Obliž vzemite iz vrečice in ga takoj uporabite.
The influence of renal impairment on the pharmacokinetics of fentanyl is expected to be limited because urinary excretion of unchanged fentanyl is less than 10% and there are no known active metabolites eliminated by the kidney. 
Okvara ledvic Vpliv okvare ledvic na farmakokinetiko fentanila je majhen, ker se nespremenjen fentanil izloča z urinom v manj kot 10%, aktivni presnovki, ki bi se izločali preko ledvic, pa niso znani.
• Gently tear or cut off the edge of the sachet completely (if you use scissors, cut close to the sealed edge of the sachet to avoid damaging the patch) 
• Previdno po celotni dolžini odtrgajte ali odrežite rob blazinice (blizu zavarjenega roba blazinice, da ne poškodujete obliža).
Application site hypersensitivity, Drug withdrawal syndrome, Pyrexia* 
preobčutljivost na mestu namestitve, sindrom odtegnitve zdravila, pireksija*
Non-epileptic (myo)clonic reactions can occur. 
Lahko se pojavijo (mio)klonične reakcije, ki niso posledica epilepsije.
The extent of interaction with strong CYP3A4 inhibitors is expected to be greater than with weak or moderate CYP3A4 inhibitors. 
Pričakovati je večji obseg interakcij z močnimi zaviralci CYP3A4 kot s šibkimi ali zmernimi zaviralci CYP3A4.
By the end of the second 72-hour application, a steady-state serum concentration is reached and is maintained during subsequent applications of a patch of the same size. 
Do konca druge 72 urne aplikacije je doseženo dinamično ravnovesje, ki se nato vzdržuje pri nadaljnih uporabah obližev enake velikosti.
Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity. 
Neklinični podatki na osnovi običajnih študij toksičnosti pri ponavljajočih odmerkih ne kažejo posebnega tveganja za človeka.
After the first DUROGESIC application, serum fentanyl concentrations increase gradually, generally leveling off between 12 and 24 hours and remaining relatively constant for the remainder of the 72-hour application period. 
Po začetni aplikaciji zdravila DUROGESIC serumske koncentracije fentanila postopno naraščajo, se po približno 12-24 urah ustalijo in nato ostanejo sorazmerno konstantne do 72 ur po aplikaciji.
Severe and unpredictable interactions with MAOIs, involving the potentiation of opiate effects or the potentiation of serotoninergic effects, have been reported. 
Poročani so bili primeri hudih in nepredvidljivih interakcij z zaviralci MAO, vključno s povečanimi opioidnimi ali serotoninergičnimi učinki.
DUROGESIC is for transdermal use. 
Zdravilo DUROGESIC je za transdermalno uporabo.
Moreover, because fentanyl passes through the placenta, the use of DUROGESIC during childbirth might result in respiratory depression in the newborn infant. 
Ker fentanil prehaja skozi placento, bi uporaba zdravila DUROGESIC med porodom lahko povzročila depresijo dihanja pri novorojencu.
This delay is due to the gradual increase in serum fentanyl concentration in the 24 hours following initial patch application. 
Razlog je v postopnem večanju koncentracije fentanila v prvih 24-ih urah po prvi aplikaciji obliža.
Some patients may experience significant respiratory depression with DUROGESIC; patients must be observed for these effects. 
Pri nekaterih bolnikih se med uporabo zdravila DUROGESIC lahko pojavi resna depresija dihanja, zato je treba bolnike skrbno spremljati.
Severe respiratory depression. 
Huda depresija dihanja.
• Some antibiotics used to treat infection (such as erythromycin or clarithromycin). 
• Nekatere antibiotike za zdravljenje okužb (kot sta eritromicin ali klaritromicin).
DUROGESIC and associated names (see Annex I) 12 micrograms/hour transdermal patch DUROGESIC and associated names (see Annex I) 25 micrograms/hour transdermal patch DUROGESIC and associated names (see Annex I) 50 micrograms/hour transdermal patch DUROGESIC and associated names (see Annex I) 75 micrograms/hour transdermal patch DUROGESIC and associated names (see Annex I) 100 micrograms/hour transdermal patch 
DUROGESIC in povezana imena (glejte Prilogo I ) 12 mikrogramov/h transdermalni obliž DUROGESIC in povezana imena (glejte Prilogo I) 25 mikrogramov/h transdermalni obliž DUROGESIC in povezana imena (glejte Prilogo I) 50 mikrogramov/h transdermalni obliž DUROGESIC in povezana imena (glejte Prilogo I) 75 mikrogramov/h transdermalni obliž DUROGESIC in povezana imena (glejte Prilogo I) 100 mikrogramov/h transdermalni obliž
DUROGESIC should not be used during childbirth as the medication can affect the breathing of the newborn child. 
Zdravila DUROGESIC ne smete uporabljati med porodom, saj lahko vpliva na dihanje novorojenčka.
{Name and address} <{tel}> <{fax}> <{e-mail}> <This medicinal product is authorised in the Member States of the EEA under the following names:> <{Name of the Member State}> <{Name of the medicinal product}> <{Name of the Member State}> <{Name of the medicinal product}> [See Annex I - To be completed nationally] 
To zdravilo je odobreno v državah članicah EGP pod naslednjimi imeni:
If discontinuation of DUROGESIC is necessary, replacement with other opioids should be gradual, starting at a low dose and increasing slowly. 
Če je potrebno zdravljenje z zdravilom DUROGESIC prekiniti, mora biti nadomeščanje z drugimi opioidi postopno; začnemo z majhnimi odmerki, ki jih postopno povečujemo.
The safety of DUROGESIC was evaluated in 3 open-label studies in 289 paediatric subjects with chronic pain, aged 2 to 17 years, inclusive. 
Varnost zdravila DUROGESIC so ocenili v 3 odprtih študijah pri 289 pediatričnih preiskovancih s kroničnimi bolečinami, starih od 2 do 17 let.
Following DUROGESIC application, the skin under the system absorbs fentanyl, and a depot of fentanyl concentrates in the upper skin layers. 
Po namestitvi zdravila DUROGESIC koža pod njim absorbira fentanil in depo fentanila je koncentriran v zgornjih plasteh kože.
Central nervous system depressants may increase the respiratory depression (see section 4.5). 
Zdravila z delovanjem na osrednje živčevje lahko poslabšajo depresijo dihanja (glejte poglavje 4.5).
• The following table shows you when to change your patch: 
• Spodnja preglednica vam prikazuje na kateri dan v tednu morate obliž zamenjati:
Adjustment of the individual fentanyl dose must be based on the patient's response and level of tolerance. 
Prilagajanje odmerka fentanila pri vsakem posameznem bolniku mora temljiti na njegovem odzivu in stopnji tolerance.
In young children, the upper back is the preferred location to minimize the potential of the child removing the patch. 
Pri majhnih otrocih se priporoča aplikacija na zgornji del hrbta, da kar se da zmanjšamo možnost, da si otrok sam odstrani obliž.
The major metabolite, norfentanyl, and other metabolites are inactive. 
Glavni presnovek norfentanil in ostali presnovki niso aktivni.
What DUROGESIC is and what it is used for What you need to know before you use DUROGESIC How to use DUROGESIC 
Kaj je zdravilo DUROGESIC in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo DUROGESIC Kako uporabljati zdravilo DUROGESIC
0.23b diamorphine oral parenteral 
0,23b diamorfin peroralna parenteralna
cyproheptadine, diphenhydramine, or hydroxyzine). 
ciproheptadin, difenhidramin ali hidroksizin).
There was no indication of teratogenic effects in studies in two species (rats and rabbits). 
V študijah na dveh živalskih vrstah (podgane in kunci) ni bilo nobenih znakov teratogenih učinkov.
If paralytic ileus is present or suspected, treatment with DUROGESIC should be stopped. 
Če je prisoten paralitični ileus ali sum nanj, je potrebno zdravljenje z zdravilom DUROGESIC prekiniti.
Monoamine Oxidase Inhibitors (MAOI) 
Zaviralci monoaminooksidaze (zaviralci MAO)
Use of DUROGESIC during childbirth is not recommended because it should not be used in the management of acute or postoperative pain (see section 4.3). 
Uporaba zdravila DUROGESIC med porodom ni priporočljiva, ker se fentanil ne sme uporabljati za lajšanje akutnih ali pooperativnih bolečin (glejte poglavje 4.3).
The potential for serious or life-threatening hypoventilation exists regardless of the dose of DUROGESIC transdermal system administered. 
Obstaja možnost pojava resne ali življenjsko nevarne hipoventilacije, neodvisno od odmerka zdravila DUROGESIC.
Eczema, Dermatitis allergic, Skin disorder, 
eritem ekcem, alergijski dermatitis, bolezni kože, dermatitis, kontaktni dermatitis
The patch should be used only on the skin of the person for whom it has been prescribed. 
Prenos obliža na drugo osebo Obliž je namenjen samo uporabi na koži bolnika, kateremu je zdravilo predpisal zdravnik.
The dose should be titrated individually on the basis of average daily use of supplemental analgesics, until a balance between analgesic efficacy and tolerability is attained. 
Odmerek je treba prilagajati individualno in upoštevati povprečni dnevni odmerek dodatnega analgetičnega zdravljenja, dokler ne dosežemo ravnovesja med analgetično učinkovitostjo in prenašanjem zdravila.
Of these 110 subjects, 23 (20.9%) had previously been receiving <30 mg of oral morphine equivalents per day, 66 (60.0%) had been receiving 30 to 44 mg of oral morphine equivalents per day, and 12 (10.9%) had been receiving at least 45 mg of oral morphine equivalents per day (data not available for 9 [8.2%] subjects). 
Od teh 110 bolnikov jih je 23 (20,9 %) predhodno prejemalo odmerek opioida, ki ustreza < 30 mg peroralnega morfina na dan, 66 (60 %) jih je prejemalo odmerek opioida, ki ustreza 30 do 40 mg peroralnega morfina na dan in 12 (10,9 %) jih je prejemalo odmerek opioida, ki ustreza najmanj 45 mg peroralnega morfina na dan (za 9 [8,2 %] preiskovancev pa ni dostopnih podatkov).
Central Nervous System conditions including increased intracranial pressure DUROGESIC should be used with caution in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. 
Zdravilo DUROGESIC je treba uporabljati previdno pri bolnikih, ki so lahko posebej dovzetni za intrakranialne učinke zadrževanja CO2, npr. pri bolnikih z zvišanim intrakranialnim tlakom, motnjami zavesti ali komo.
Pharmacokinetic/Pharmacodynamic Relationships 
Farmakokinetično/farmakodinamično razmerje
Your doctor will be able to tell you how long you can expect to use the patches 
kako dolgo lahko pričakujete, da boste uporabljali obliže.
Initial evaluation of the maximum analgesic effect of DUROGESIC cannot be made before the patch is worn for 24 hours. 
Maksimalnega analgetičnega učinka zdravila DUROGESIC ne moremo ovrednotiti, dokler bolnik ne nosi obliža 24 ur.
To prevent overdose it is recommended that opioid-naïve patients receive low doses of immediate-release opioids (eg, morphine, hydromorphone, oxycodone, tramadol, and codeine) that are to be titrated until an analgesic dosage equivalent to DUROGESIC with a release rate of 12 mcg/h or 25 mcg/h is attained. 
Da bi preprečili preveliko odmerjanje, je pri bolnikih, ki še niso prejemali opioidov, priporočljivo titrirati odmerek z majhnimi odmerki opioidov s takojšnjim sproščanjem (npr. morfin, hidromorfon, oksikodon, tramadol in kodein), dokler ne dosežemo ekvianalgetičnega odmerka za zdravilo DUROGESIC s stopnjo sproščanja 12 mikrogramov/h ali 25 mikrogramov/h.
Opioids increase the tone and decrease the propulsive contractions of the smooth muscle of the gastrointestinal tract. 
Opioidi povečajo tonus in zmanjšajo propulzivna krčenja gladkega mišičja v prebavilih.
Hypoaesthesia, Convulsion (including clonic convulsions and grand mal convulsion), Amnesia, Depressed level of consciousness, Loss of consciousness 
(vključno z kloničnimi in konvulzijami grand mal), amnezija, zmanjšana stopnja zavesti, izguba zavesti
In general, the discontinuation of opioid analgesia should be gradual in order to prevent withdrawal symptoms (see section 4.8). 
Splošno velja, da mora biti za preprečitev pojava odtegnitvenih simptomov ukinitev opioidne analgezije postopna (glejte poglavje 4.8).
Previous analgesic therapy should therefore be gradually phased out after the initial dose application until analgesic efficacy with DUROGESIC is attained. 
Predhodno analgetično terapijo zato ukinjamo postopno, v času od prve uporabe obliža do doseženega analgetičnega učinka z zdravilom DUROGESIC.
• Heart beat feels fast or uneven (palpitations, tachycardia) 
• hiter ali nenormalen srčni utrip (palpitacije, tahikardija)
The simulations suggest that the steady-state AUC of patients with Child-Pugh Grade B liver disease (Child-Pugh Score = 8) would be approximately 1.36 times larger compared with that of patients with normal liver function (Grade A; Child-Pugh Score = 5.5). 
Simulacije kažejo, da bi bila AUC bolnikov z okvaro jeter Child-Pugh razreda B (stopnja Child-Pugh = 8) v stanju dinamičnega ravnovesja približno 1,36-krat večja v primerjavi z bolniki z normalnim delovanjem jeter (razred A,
It is recommended that DUROGESIC be used in patients who have demonstrated opioid tolerance. 
Priporočljivo je, da zdravilo DUROGESIC uporabljajo bolniki, ki so že razvili toleranco na opioide.
• It may take some time for your first patch to have its maximum effect. 
• Da začne vaš prvi obliž v celoti delovati, lahko traja nekaj časa.
The effects of the inducer decline gradually and may result in increased fentanyl plasma concentrations, which could increase or prolong both the therapeutic and adverse effects, and may cause serious respiratory depression. 
Učinki induktorja postopoma upadajo in lahko povzročijo zvečanje plazemskih koncentracij fentanila, to pa lahko poveča ali podaljša terapevtski učinek in neželene učinke ter povzroči hudo depresijo dihanja.
DUROGESIC may interact with these medicines and you may experience changes to mental status such as feeling agitated, seeing, feeling, hearing, or smelling things that are not there (hallucinations) and other effects such as changing blood pressure, fast heart beat, high body temperature, overactive reflexes, lack of coordination, muscle stiffness, nausea, vomitting and diarrhoea. 
Zaradi možnega mesdebojnega delovanja zdravila DUROGESIC in temi zdravili lahko pri vas pride do sprememb duševnega stanja, kot so vznemirjenost, videnje, čutenje, slišanje ali vohanje stvari, ki jih ni (halucinacije) in drugih učinkov, kot so sprememba krvnega tlaka, hiter srčni utrip, visoka telesna temperatura, pretirane refleksne reakcije, pomanjkanje koordinacije, okorelost mišic, slabost, bruhanje in driska.
Data in subjects with cirrhosis and simulated data in subjects with different grades of impaired liver function treated with transdermal fentanyl suggest that fentanyl concentrations may be increased, and fentanyl clearance may be decreased compared to subjects with normal liver function. 
Podatki o bolnikih s cirozo in simulirani podatki pri preiskovancih z različnimi stopnjami okvare jeter, zdravljenih s transdermalnim fentanilom, kažejo, da so lahko koncentracije fentanila zvečane, očistek fentanila pa zmanjšan v primerjavi s preiskovanci z normalnim delovanjem jeter.
The appropriate initiating dose of DUROGESIC should be based on the patient's current opioid use. 
Primeren začetni odmerek zdravila DUROGESIC mora biti določen na podlagi trenutne uporabe opioidov pri bolniku.
Caution is advised when DUROGESIC is co-administered with medicinal products that affect the serotonergic neurotransmitter systems. 
Pri predpisovanju zdravila DUROGESIC sočasno z zdravili, ki vplivajo na serotoninergični nevrotransmiterski sistem, je potrebna previdnost.
• Unusual feeling in the skin, such as tingling or crawling feelings (paraesthesia) 
• nenavaden občutek na koži kot je mravljinčenje ali zbadanje (parestezija)
Respiratory depression may persist beyond the removal of the DUROGESIC patch. 
Depresija dihanja lahko traja še po odstranitvi transdermalnega obliža DUROGESIC.
• Do not use soap or any other cleansers, creams, moisturisers, oils or talc before applying the patch 
• Pred namestitvijo obliža ne uporabljajte mil ali drugih čistilnih sredstev, krem, losijonov, olj ali smukca.
DUROGESIC should be applied to non-irritated and non-irradiated skin on a flat surface of the torso or upper arms. 
Transdermalni obliž DUROGESIC je treba prilepiti na nerazdraženo in neobsevano kožo, na ravno površino zgornjega dela trupa ali nadlakti.
Fentanyl is an opioid analgesic, interacting predominantly with the µ opioid receptor. 
Mehanizem delovanja Fentanil je opioidni analgetik, ki se veže predvsem na µ-opioidne receptorje.
How to store DUROGESIC Contents of the pack and other information 
Shranjevanje zdravila DUROGESIC Vsebina pakiranja in dodatne informacije
Stopping suddenly may make you feel unwell 
Če jih boste nenadoma prenehali uporabljati, se boste morda počutili slabo.
The safety profile in children and adolescents treated with DUROGESIC was similar to that observed in adults. 
Varnostni profil neželenih učinkov je bil pri otrocih in mladostnikih, ki so prejemali zdravilo DUROGESIC, podoben kot pri odraslih.
• Medicines used to treat HIV infection (such as ritonavir). 
• Zdravila za zdravljenje okužbe z virusom HIV (kot je ritonavir).
If you switch from a different painkiller to DUROGESIC or if you suddenly stop using DUROGESIC, you may notice withdrawal effects such as sickness, feeling sick, diarrhoea, anxiety or shivering. 
Če boste prešli z drugega protibolečinskega zdravila na zdravilo DUROGESIC ali če nenadoma prenehate uporabljati zdravilo DUROGESIC, boste morda opazili odtegnitvene učinke zdravila, kot so slabost, bruhanje, driska, občutek tesnobe in drgetanje.
Make sure it sticks well, especially the edges 
Prepričajte se, da se je obliž dobro prilepil na kožo, zlasti na robovih.
• Itching, skin rash or redness of the skin 
• srbenje, kožni izpuščaj ali pordela koža
The concomitant use of CYP3A4 inhibitors and DUROGESIC is not recommended, unless the patient is closely monitored (see section 4.4). 
Sočasna uporaba zaviralcev CYP3A4 in zdravila DUROGESIC ni priporočljiva, razen če je bolnik pod skrbnim nadzorom (glejte poglavje 4.4).
• If you forget, change your patch as soon as you remember and make note of the day and time. 
Če ste pozabili zamenjati obliž • Če ste pozabili zamenjati obliž, ga zamenjajte takoj, ko se spomnite in si zabeležite dan in čas.
The dosage may subsequently be titrated upwards or downwards, if required, in increments of either 12 or 25 mcg/h to achieve the lowest appropriate dosage of DUROGESIC depending on response and supplementary analgesic requirements. 
ZMANJŠAMO, ČE JE POTREBNO, V ODMERKIH PO 12 ALI 25 MIKROGRAMOV/H, DOKLER NE DOSEŽEMO NAJMANJŠEGA PRIMERNEGA ODMERKA ZDRAVILA DUROGESIC, ODVISNO OD BOLNIKOVEGA ODZIVA IN DODATNIH POTREB PO ANALGETIKU.
If the site of DUROGESIC application requires cleansing prior to application of the patch, this should be done with clear water. 
Če je treba kožo pred uporabo zdravila DUROGESIC očistiti, to naredimo s čisto vodo.
• Your upper body or arm 
• zgornji del telesa ali rame
DUROGESIC should be administered to only those opioid-tolerant paediatric patients (ages 2 to 16 years) who are already receiving at least 30 mg oral morphine equivalents per day. 
Zdravilo DUROGESIC se sme uporabiti samo pri pediatričnih bolnikih (starih od 2 do 16 let), ki dobro prenašajo opioide in že prejemajo odmerek opioida, ki ustreza vsaj 30 mg peroralnega morfina/dan.
High inter-subject variability in plasma concentrations has been observed. 
Opažali so velike razlike v plazemskih koncentracijah med posamezniki.
DUROGESIC should be used with caution in patients with brain tumours. 
Zdravilo DUROGESIC je treba previdno uporabljati tudi pri bolnikih z možganskimi tumorji.
DUROGESIC should not be used during pregnancy unless you have discussed this with your doctor. 
Zdravila DUROGESIC ne smete uporabljati med nosečnostjo, razen če ste se o tem pogovorili z zdravnikom.
Therefore, the concomitant use of DUROGESIC and CYP3A4 inhibitors is not recommended unless the benefits outweigh the increased risk of adverse effects. 
Sočasna uporaba zdravila DUROGESIC in zaviralcev CYP3A4 ni priporočljiva, razen kadar koristi odtehtajo zvečano tveganje za pojav neželenih učinkov.
Dose titration and maintenance therapy The DUROGESIC patch should be replaced every 72 hours. 
Titracija odmerka in vzdrževalno zdravljenje Transdermalni obliž DUROGESIC je treba zamenjati vsakih 72 ur.
The potential for serious or life-threatening hypoventilation exists even if the lowest dose of DUROGESIC is used in initiating therapy in opioid-naïve patients, especially in elderly or patients with hepatic or renal impairment. 
Verjetnost za pojav resne ali življenjsko nevarne hipoventilacije obstaja celo pri pri uvajanju zdravila DUROGESIC v najmanjšem odmerku bolnikom, ki še niso jemali opioidov, še posebej starejšim bolnikom in bolnikom z okvaro jeter ali ledvic.
To remove the patch from the protective sachet, locate the pre-cut notch (indicated by an arrow on the patch label) along the edge of the seal. 
Za odpiranje vrečice poiščemo zarezo na robu blazinice (označena je s puščico).
1a parenteral buprenorphine sublingual parenteral codeine oral parenteral 
1a parenteralna buprenorfin sublingvalna parenteralna kodein peroralna parenteralna